Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Oncolys Aims to Bring Nucleocapsid Inhibitor into Clinic Next Year for COVID-19 Treatment
Oncolys BioPharma plans to initiate a clinical trial next year for OBP-2011, an oral COVID-19 treatment with a novel mechanism of action. The drug is intended for use early in coronavirus infections, but is potentially effective even if its administration…
To read the full story
Related Article
- Oncolys’ Nucleocapsid Inhibitor Effective against Omicron, PI Launch by Year-End
February 1, 2022
- Oncolys’ Oral COVID-19 Drug Effective in Hamster Model
October 27, 2021
BUSINESS
- Hisamitsu Sets April 17 Shareholders Meeting to Approve Squeeze-Out
March 16, 2026
- AbbVie Japan Files Rinvoq for Vitiligo
March 16, 2026
- SSP Appoints Yoko Motoshima as New President
March 16, 2026
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…